M. Burotto

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

R. Motzer, B. Escudier, A. Shah, 2024, ESMO open.

Predictors of response to immunotherapy in colorectal cancer.

Jaime González-Montero, M. Burotto, Carlos I Rojas, 2024, The oncologist.

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

A. Poprach, G. De Velasco, L. Albiges, 2024, The New England journal of medicine.

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

T. Ciuleanu, J. Vuky, G. Kollia, 2024, Journal for immunotherapy of cancer.

Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.

M. S. van der Heijden, M. D. Galsky, M. Claps, 2024, Journal of Clinical Oncology.